Phreesia (PHR) Stock Price, News & Analysis

Company Overview

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.

Key Stats

• Today's Range: $19.01 to $20.04
• 50-Day Range: $18.04 to $24.44
• 52-Week Range: $14.55 to $29.16
• Volume: 292,863 shs
• Average Volume: 449,216 shs
• Market Capitalization: $1.15 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $29.42
• Consensus Rating: Moderate Buy

Phreesia Stock Analysis - MarketRank™

Phreesia scored higher than 92% of companies evaluated by MarketBeat, and ranked 105th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Phreesia has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Phreesia has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Phreesia are expected to grow in the coming year, from ($1.23) to ($0.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Phreesia is -11.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Phreesia is -11.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Phreesia has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.09% of the outstanding shares of Phreesia have been sold short.

Short Interest Ratio / Days to Cover

Phreesia has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Phreesia has recently increased by 11.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Phreesia does not currently pay a dividend.

Dividend Growth

Phreesia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.60

Percentage of Shares Shorted

5.09% of the outstanding shares of Phreesia have been sold short.

Short Interest Ratio / Days to Cover

Phreesia has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Phreesia has recently increased by 11.79%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.79

News Sentiment

Phreesia has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Phreesia this week, compared to 4 articles on an average week.

Search Interest

1 people have searched for PHR on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Phreesia to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Phreesia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,035,226.00 in company stock.

Percentage Held by Insiders

Only 5.80% of the stock of Phreesia is held by insiders.

Percentage Held by Institutions

92.10% of the stock of Phreesia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PHR Stock Analysis - Frequently Asked Questions

How have PHR shares performed this year?

Phreesia's stock was trading at $23.15 at the beginning of 2024. Since then, PHR stock has decreased by 14.2% and is now trading at $19.87.
View the best growth stocks for 2024 here.

How were Phreesia's earnings last quarter?

Phreesia, Inc. (NYSE:PHR) issued its earnings results on Wednesday, September, 4th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.06. The company earned $102.12 million during the quarter, compared to the consensus estimate of $101.76 million. Phreesia had a negative trailing twelve-month return on equity of 39.34% and a negative net margin of 25.73%.

When did Phreesia IPO?

Phreesia (PHR) raised $127 million in an IPO on Thursday, July 18th 2019. The company issued 7,800,000 shares at $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray served as the underwriters for the IPO.

Who are Phreesia's major shareholders?

Top institutional shareholders of Phreesia include FMR LLC (11.59%), Champlain Investment Partners LLC (4.33%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.66%) and State Street Corp (2.30%). Insiders that own company stock include Chaim Indig, Evan Roberts, David Linetsky, Randy Rasmussen, Allison C Hoffman, Amy Beth Vanduyn, Balaji Gandhi, Michael J Davidoff, Janet Gunzburg, Yvonne Hui and Gillian Munson.
View institutional ownership trends.

How do I buy shares of Phreesia?

Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Phreesia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Phreesia investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Arista Networks (ANET) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 9/04/2024
• Today: 11/22/2024
• Next Earnings (Confirmed): 12/09/2024
• Fiscal Year End: 1/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Business services, not elsewhere classified
• Sub-Industry: Business Services
• Current Symbol: NYSE:PHR
• CUSIP: N/A
• CIK: 1412408
• Web: www.phreesia.com
• Phone: (888) 654-7473
• Fax: 646-607-1776
• Employees: 1,438
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $29.42
• High Stock Price Target: $34.00
• Low Stock Price Target: $23.00
• Potential Upside/Downside: +48.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-136,880,000.00
• Net Margins: -25.73%
• Pretax Margin: -25.25%
• Return on Equity: -39.34%
• Return on Assets: -27.13%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 1.77
• Quick Ratio: 1.77

Sales & Book Value

• Annual Sales: $389.96 million
• Price / Sales: 2.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.52 per share
• Price / Book: 4.40

Miscellaneous

• Outstanding Shares: 57,773,000
• Free Float: 54,422,000
• Market Cap: $1.15 billion
• Optionable: Optionable
• Beta: 0.94